Aurobindo Pharma Limited received FDA approval for the generic formulation of its ALFUZOSIN HYDROCHLORIDE oral tablets, broadening the company’s portfolio and introducing immediate competition into the established urology market segment. Expected to lower treatment costs for patients and payers, this regulatory clearance positions Aurobindo to compete with the branded alternative for market share.